Slides
Page 1
Zymeworks Portfolio Update OCTOBER 27, 2026 ZW209 Licensing Agreement and New Clinical Data for ZW191
Page 2
2 This presentation includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding implementation of its long-term strategy to maximize value creation; Zymeworks’ and its partners’ clinical development of product candidates; potential safety profile and therapeutic effects of product candidates; the commercial potential of technology platforms and product candidates; the anticipated benefits of its collaboration agreements; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, “preserve”, “intend”, “could”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; uncertainties regarding the commercial success of YUPELRI® and TRELEGY; Zymeworks may not achieve milestones or receive additional payments or royalties under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful stockholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue- generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; data providing early validation of our antibody drug conjugate platform and next generation pipeline programs may not be replicated in future studies; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; the inability of Zymeworks to identify and consummate a strategic acquisition; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca). Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward- looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Legal disclaimer
Page 3
3 Strategic Differentiation: innovative R&D engine with royalty portfolio for multi- component BD Fully integrated discovery-to-early-stage development to support internally discovered and externally acquired assets ROYALTY PORTFOLIO R&D Generates Future Royalties and Milestones via Partnerships Acquisitions Generate Revenue and Future Pipeline Opportunities R&D ENGINE Diversified portfolio of partnered or acquired productsShare Repurchases
Page 4
4 Zymeworks partnering model has paid almost $1B Royalties Upfronts & Milestones Jazz Ziihera® (zanidatamab-hrii) BeOne Ziihera® (zanidatamab-hrii) Janssen Pasritamig (Azymetric and EFECT) GSK Phase 1 program (Azymetric and EFECT) GSK Preclinical program (Azymetric and EFECT) Merck Phase 1 program (Azymetric and EFECT) Daiichi Phase 1 program (Azymetric and EFECT) Roche ZW209 $650.0M $1.1B $81.0M $83.0M $204.0M 1 $23.0M $1.1B $1.1B $7.3M $55M $758M $921.8M ■ Pending upfront payment following HSR clearance ■ Received to date ■ Remaining Tiered 10 to 20% Tiered high single-digit to 20% Tiered mid-single digits Tiered low to mid-single digits Tiered worldwide royalties Tiered high-single-digit to mid-teens Tiered low to mid-single digits $230.3MTiered low-single-digit to mid-single $27.6M 1. 204.0M remaining milestones are related to Pasritamig only, and do not include additional milestones that may be payable in relation to another deprioritized asset. $144.0M *Bars not to scale. Values rounded to the nearest million
Page 5
5 Differentiated pipeline of multifunctional therapeutics Program Technology Target Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Solid Tumor Oncology: Antibody-Drug Conjugates (ADC) ZW191 Topo1i ADC | DAR 8 | Fc WT ZD06519 Payload FRα Gynecological Thoracic ZW251 Topo1i ADC | DAR 4 | Fc WT ZD06519 Payload GPC3 HCC, CGT, sqNSCLC ZW220 Topo1i ADC | DAR 4 | Fc Mut ZD06519 Payload NaPi2b Gynecological Thoracic ZW327* Topo1i ADC | DAR 8 | Fc Mut ZD06519 Payload Ly6E Multiple indications ZW427* RASi ADC | DAR 8 | Fc Silent RASi Payload Ly6E Lung and GI ZW418* RASi ADC | DAR 8 | Biparatopic RASi Payload Biparatopic PTK7 Lung ZW439* RASi ADC | DAR 8 | Fc Silent RASi Payload Claudin18.2 Pancreatic Solid Tumor Oncology: Multispecific Antibody Therapeutics (MSAT) ZW209 Trispecific TCE | Tri-TCE Costim Azymetric , Novel anti-CD3 Conditional CD28 DLL3 x CD3 x CD28 Thoracic ZW239 Trispecific TCE | Tri-TCE Costim Azymetric , Novel anti-CD3 Conditional CD28 CLDN18.2 x CD3 x CD28 Digestive System Autoimmune & Inflammatory Diseases ZW1528 Dual Cytokine Blocker Azymetric Hetero-Fab | YTE IL4Rα x IL-33 ZW1572 Dual Cytokine Blocker Azymetric Hetero-Fab | YTE IL4Rα x IL-31 NCT06555744 NCT07164313 Anticipated IND in 2026 Anticipated regulatory submission in 2027
Page 6
ZW209: Roche Licensing Agreement Overview 6 Adam Schayowitz Head of R&D
Page 7
Meaningful return from upfront with substantial potential upside from milestones and royalties 7 Bars not to scale Royalties: high-single-digit to mid-teen digits, into the 2040s Roche to fund all research and development of ZW209, including the Phase 1a trial. Roche will be responsible for subsequent development and commercialization. R&D Upfront Payment Near Term Development and Commercial Milestones Royalties Net $55M Upfront $40M Ph1b Start Royalties$718M in Milestones
Page 8
8 Collaboration combines Zymeworks’ innovation while leveraging Roche’s capabilities to accelerate and expand development • Global capabilities to accelerate and broaden development across multiple lines of therapy • Roche brings commercial experience in first line ES-SCLC with established prescribers, payer and trial networks. • Roche’s pipeline includes additional programs which may provide combination • ZW209 development leverages Zymeworks proprietary, and clinically validated, Azymetric platform • Zymeworks’ utilizes decades of extensive paratope and format exploration to enable discovery of optimal TriTCEs • Zymeworks to run the global Phase 1a study, leveraging proven development capabilities for speed and execution, with no handover required. ZW209 IND Clearance Complete1 Phase 1a global study to be Initiated by Zymeworks • First patient dosed expected in 2026 Roche responsible for subsequent development 3 2 ES-SCLC: Extensive-stage small-cell lung cancer Agreement remains subject to HSR clearance
Page 9
ZW209: Preclinical Development 9 Paul Moore Chief Scientific Officer
Page 10
10 Low T cell infiltration and T cell anergy remain challenges in the treatment of solid tumors with traditional bispecific T Cell Engagers CD3: cluster of differentiation 3 protein complex and T cell co-receptor; TAA: tumor associated antigen; TCE: T cell engager; TC R: T cell receptor; TriTCE Co-Stim: trispecific T cell engager co-stimulatory program. Arvedson T et al. Ann Rev Cancer Biol 2022. Zymeworks Trispecific Co-Stimulatory TCE: Overcoming Lack of Efficacy and Durability of Responses in Solid Tumors by Incorporating Conditional Costimulation Zymeworks’ Next Generation Solution: • Balanced CD3 and CD28 affinity engagement • Conditional CD28 binding that only binds in cis with CD3 engagement • Strict target-dependent activity and T cell activation • Identified via Azymetric screening of various antibody geometries and CD3 and CD28 paratope affinities CD28 biology provides ideal costimulatory pathway to integrate with CD3 TCE to enhance and sustain anti- tumor T cell responses
Page 11
Extensive Paratope And Format Exploration Enables Discovery Of Optimal Costimulatory TCEs 11 Locked CD3/CD28 geometry: optimized for efficient conditional cis CD28 co-stimulation and strict TAA dependence T cell Tumor cell CD28 CD3 TAA in vitro Activity & Differentiation AzymetricTM Enabled HTP Format Engineering & Production Computational & AI Guided Paratope Engineering Early Developability Assessment TAA Multiple epitopes CD3 CD28 Iterative HTP lab-in-loop screening
Page 12
12 Future TriTCE Co-stim Programs Program Technology Target(s) Indication Discovery Candidate Selection Preclinical Phase 1 Phase 2 Phase 3 Oncology ZW209 Trispecific TCE | TriTCE Co-Stim Azymetric , EFECTTM, TriTCE Co-Stim DLL3 Thoracic ZW239 Trispecific TCE | TriTCECo-Stim Azymetric , EFECTTM, TriTCE Co-Stim CLDN18.2 Digestive System ZW335 Trispecific TCE | TriTCE Co-Stim Azymetric , EFECTTM, TriTCE Co-Stim Undisclosed Colorectal Cancer ZW1953 Logic-gated TCE | TriTCE Co-Stim Azymetric , EFECTTM, TriTCE Co-Stim Undisclosed AML ZW437 Trispecific TCE | TriTCE Co-Stim Azymetric , EFECTTM, TriTCE Co-Stim Undisclosed Multi-indication solid tumor ZW463 Trispecific TCE | TriTCE Co-Stim Azymetric , EFECTTM, TriTCE Co-Stim Undisclosed Prostate Cancer Novel Target TriTCE Co-Stim Trispecific TCE | TriTCE Co-Stim Azymetric , EFECTTM, TriTCE Co-Stim Undisclosed Multi-indication solid tumor
Page 13
ZW209 Trispecific T cell engager (TriTCE) Designed to Target DLL3-expressing Solid Tumors Expected Phase 1 Initiation, in collaboration with Roche, in 2026. 1. https://www.yalemedicine.org/conditions/small-cell-lung-cancer DLL3: Delta-like ligand 3; SCLC: Small Cell Lung Cancer; TAA: tumor-associated antigen; TriTCE: Tri-specific T Cell Engager. Optimized design Potential first-in-class TriTCE Co-Stim targeting eradication of DLL3-expressing tumor cells through simultaneous engagement of CD3 and CD28 on T cells Optimized DLL3, CD3, CD28 binding affinities and coordinated binding geometry using Azymetric and EFECT platforms Leverages obligate cis-T cell binding and conditional CD28 engagement to prevent unintended T cell activation and T cell fratricide, while enabling tumor-targeted cytotoxicity Differentiated profile Superior in vitro and in vivo pharmacology profile relative to DLL3 x CD3 bispecifics including Tarlatamab Integrated co-stimulation increases target-dependent T cell proliferation, survival and anti- tumor activity No T cell activation or cytokine activation in absence of DLL3 target cells, no T cell fratricide Well tolerated at high dose in nonhuman primates displaying antibody like pharmacokinetics Significant patient need DLL3 is expressed on the surface of SCLC and other neuroendocrine tumors but rarely on the surface of normal cells SCLC accounts for about 15% of all lung cancer diagnoses in the U.S. each year1 13
Page 14
14 ZW209: DLL3 TCE designed for optimal T cell activation Tumor Cell Cytotoxicity (%) Sustained cytotoxicity relative to bispecific TCEs over repeated stimulations ZW209 AMG 757† ZW209 CD28null Naïve TEMRA Improved in vitro potency on DLL3 tumor cells relative to benchmarks TCM TEM % Change from Day 0 Day 7 Lau D et al., Abstract #7318 presented at AACR 2025; mAb: monoclonal antibody; TCEs: T Cell Engagers. AMG 757/tarlatamab Anti-tumor activity in mouse tumor models ZW209 exhibits in vivo anti-tumor activity in an admixture NCI-H82 xenograft model Conditional binding of CD28, requiring co-engagement of CD3 ZW209 supports sustained T cell fitness while expanding memory T cell populations ZW209 displays superior cytotoxicity relative to bispecific and trispecific clinical TCE benchmarks across multiple DLL3-positive SCLC tumor cell lines in assays with low E:T ratio (E:T = 1:4) • No target-independent cytokine release in PBMC donor- based solid or liquid phase assays • Well tolerated in human immune engrafted mouse model and NHP with no elevated systemic cytokines. Displays antibody like PK.
Page 15
ZW191: New Clinical Data 15 Sabeen Mekan Chief Medical Officer
Page 16
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. Background and study design PART 2 DOSE OPTIMISATIONbKEY ELIGIBILITY CRITERIA • ≥18 years of age with recurrent high-grade serous or clear cell ovarian cancer • Exhausted available standard treatment options with no limit on the number of prior lines • Regardless of FRα expression • ECOG PS of 0 or 1 1:1 randomisation 9.6 mg/kg 6.4 mg/kg PROC PART 1 DOSE ESCALATIONa,b EC NSCLCPROC 1.6 mg/kg 3.2 mg/kg 4.8 mg/kg 6.4 mg/kg 8.0 mg/kg 9.6 mg/kg 11.2 mg/kg a21-day dose-limiting toxicities evaluation period. bZW191 administered IV every 3 weeks. CT/MRI testing every 6 weeks (first 4 assessments) or every 9 weeks timed from cycle 1 day 1. Safety follow-up was 30 days post last dose of ZW191; survival follow-up was every 3 months from last dose of ZW191 for up to 2 years. • Treatment options remain limited for heavily pretreated patients with platinum-resistant ovarian cancer (PROC), including those with high-grade serous and clear cell histology1 • Folate receptor alpha (FRα) is highly expressed in ovarian cancer and other solid tumours, making it a promising therapeutic target2 • ZW191 is an FRα-targeted antibody-drug conjugate comprising a protease-cleavable linker and a novel topoisomerase I inhibitor payload (ZD06519; drug-to- antibody ratio: 8)3 • ZWI-ZW191-101 (NCT06555744) is an ongoing, first- in-human, phase 1 global study evaluating the safety, tolerability, and antitumour activity of ZW191 in patients with advanced solid tumours4 We report efficacy and safety results at 6.4 and 9.6 mg/kg in participants with PROC, with a median follow-up of 7 months Data cutoff 10 September 2026. CT: computed tomography; EC: endometrial cancer; ECOG PS: Eastern Cooperative Oncology Group performance status; IV: intravenously; MRI: magnetic resonance imaging; NSCLC: non-small cell lung cancer. 1. Richardson DL, et al. JAMA Oncol. 2023;9(6):851-859. 2. Köbel M, et al. Br J Cancer. 2014;111(12):2297-2307. 3. Lawn S, et al. Clin Cancer Res. 2026;32(13):2748-2764. 4. A study of ZW191 in participants with solid tumors. ClinicalTrials.gov. Updated 7 May 2026. Accessed 2 October 2026. https://clinicaltrials.gov/study/NCT06555744.
Page 17
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. Prior therapies 6.4 mg/kg (n=37) 9.6 mg/kg (n=43) Total (N=80) Prior lines of therapy, median (range) 4 (1-10) 4 (2-9) 4 (1-10) Prior lines of therapy, n (%) 1-2 12 (32) 8 (19) 20 (25) 3-4 9 (24) 15 (35) 24 (30) ≥5 16 (43) 20 (47) 36 (45) Prior systemic therapy, n (%) Platinum and taxane 37 (100) 43 (100) 80 (100) Bevacizumab 32 (86) 35 (81) 67 (84) PARP inhibitor 18 (49) 27 (63) 45 (56) Checkpoint inhibitor 7 (19) 10 (23) 17 (21) Mirvetuximab soravtansine 2 (5) 2 (5) 4 (5) Demographics and baseline characteristics 6.4 mg/kg (n=37) 9.6 mg/kg (n=43) Total (N=80) Age, years, median (range) 61 (42-78) 61 (40-79) 61 (40-79) ≥65 years, n (%) 15 (41) 20 (47) 35 (44) Race, n (%) Asian 27 (73) 33 (77) 60 (75) White 9 (24) 9 (21) 18 (23) Other 1 (3) 1 (2) 2 (2) Baseline ECOG PS, n (%) 0 20 (54) 24 (56) 44 (55) 1 17 (46) 19 (44) 36 (45) Histology, n (%) High-grade serous 32 (86) 39 (91) 71 (89) Clear cell 5 (14) 4 (9) 9 (11) Median baseline FRα H-score was 145 (range, 0-300) and median PS2+ was 45% (range, 0%-100%) Patients were heavily pretreated and had a wide range of FRα expression ECOG PS: Eastern Cooperative Oncology Group performance status; FRα: folate receptor alpha; H: histochemical; PARP: poly adenosine diphosphate‒ribose polymerase; PS2+: positive score ≥2+.
Page 18
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. cORR was 65% at 6.4 mg/kg and 55% at 9.6 mg/kg in high-grade serous PROC Note: Response-evaluable patient data only. All clear cell patients had low/negative FRα level. High-grade serous PROC 6.4 mg/kg (n=31) 9.6 mg/kg (n=38) cORR, % (95% CI) 64.5 (45.4, 80.8) 55.3 (38.3, 71.4) DCR, % (95% CI) 100 (88.8, 100.0) 92.1 (78.6, 98.3) Clear cell PROC 6.4 mg/kg (n=5) 9.6 mg/kg (n=4) cORR, % (95% CI) 20.0 (0.5, 71.6) 0 (0, 60.2) DCR, % (95% CI) 80.0 (28.4, 99.5) 100 (39.8, 100.0) • cORR (95% CI) in HGSOC by FRα PS2+ categories – High ≥75% (n=26): 69.2% (48.2%, 85.7%) – Intermediate 25%-74% (n=22): 50.0% (28.2%, 71.8%) – Low/negative 0%-24% (n=20): 55.0% (31.5%, 76.9%) Analysis populations: All enrolled (N=80); response-evaluable (n=78); FRα-evaluable (n=77). Three patients had confirmed responses after the data cut date. One response-evaluable patient with non-evaluable FRα data was excluded from the FRα subgroup analysis. FRα expression was assessed by immunohistochemistry using archival or newly collected formalin-fixed, paraffin-embedded biopsies with the VENTANA® FOLR1 (FOLR1-2.1) assay. The PS2+ was defined as the percentage of tumour cells with 2+ and 3+ staining intensity and categorised as low/negative 0%-24%, intermediate 25%-74%, and high 75%-100%. cORR: confirmed objective response rate; DCR: disease control rate; FRα: folate receptor alpha; HGSOC: high-grade serous ovarian carcinoma; PROC: platinum-resistant ovarian cancer; PS2+: positive score ≥2+. Percentage Change From Baseline in Sum of Diameters 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 High-grade serous Clear cell Treatment ongoing ZW191 6.4 mg/kg ZW191 9.6 mg/kg 25%-74%0%-24% 75%-100% Not evaluatedFRα expression PS2+: * Prior mirvetuximab soravtansine * * * *
Page 19
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. Responses to ZW191 were deep and durable mDOR was not reached with 45% of participants continuing treatment 6.4 mg/kg 9.6 mg/kg HIGH-GRADE SEROUS mDORa NR NR mPFS, mo (95% CI) 7.9b (4.9, NR) 9.8 (4.4, 9.9) 6-month PFS, % (95% CI) 61.5 (38.4, 78.1) 61.4 (41.6, 76.2) CLEAR CELL mPFS, mo (95% CI) 4.0 (1.2, NR) 5.0 (2.6, NR) ZW191 9.6 mg/kg 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100Percentage Change From Baseline in Sum of Diameters 0 1 32 4 5 6 7 8 9 10 11 12 13 14 15 Months High-grade serous Clear cell Treatment ongoing mDOR: median duration of response; mPFS: median progression-free survival; NR: not reached; PFS: progression-free survival; PROC: platinum-resistant ovarian cancer. mPFS was evaluated based on all enrolled patients with PROC (N=80). aAt median 7 months follow-up. bEvent rate was 44% as of data cut with majority of patients on treatment. mPFS is expected to evolve. ZW191 6.4 mg/kg Percentage Change From Baseline in Sum of Diameters 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 Months 0 1 32 4 5 6 7 8 9 10 11 12 13 14 15 High-grade serous Clear cell Treatment ongoing
Page 20
Content of this presentation is copyright and responsibility of the author. Permission is required for re-use. TEAE: treatment-emergent adverse event; TRAE: treatment-related adverse event. TEAE, n (%) 6.4 mg/kg (n=37) 9.6 mg/kg (n=43) Any TEAE 35 (95) 43 (100) Grade ≥3 TEAE 20 (54) 32 (74) Grade ≥3 TRAE 8 (22) 19 (44) Serious TEAEs 16 (43) 23 (53) Serious Grade ≥3 TEAE 14 (38) 19 (44) TEAE leading to dose reduction 2 (5) 14 (33) Discontinuations due to TEAEs 5 (14) 8 (19) Deaths due to TEAEs 0 0 ZW191 was well tolerated TEAEs of any grade occurring in ≥15% of patients Patients, % ZW191 6.4 mg/kg ZW191 9.6 mg/kg Nausea Neutropenia Anaemia Constipation Fatigue Decreased appetite Aspartate aminotransferase increased Diarrhoea Alanine aminotransferase increased Thrombocytopenia Asthenia Pyrexia Vomiting 100 80 60 40 20 0 20 40 60 80 100 Any grade Grade 3 Grade 4
Page 21
21 Zymeworks originated programs highlighted at ESMO Abstract Title Key Highlights LBA40 Randomized dose optimization of ZW191 in heavily pretreated patients with platinum- resistant ovarian cancer (ZYME) • cORR of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous PROC • mDOR not yet reached at either dose level at median 7 months follow-up, with six- month PFS rate of 61% in both groups • Favorable tolerability profile, particularly at 6.4 mg/kg, supports continued clinical development in partnership or through a strategic collaboration LBA79 Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2- positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON- GEA-01 (JAZZ) • Nearly 40% of patients alive at three years with Ziihera plus tislelizumab and chemotherapy, irrespective of PD-L1 status, achieving a median OS of 27 months • Mature HERIZON-GEA-01 results show Ziihera plus chemotherapy delivered statistically significant and clinically meaningful OS benefit, reducing the rate of death by 24% versus trastuzumab plus chemotherapy • Median OS reached 27.0 months (95% confidence interval [CI]: 23.7–32.2), the longest reported in a Phase 3 trial in this setting. The Ziihera plus tislelizumab and chemotherapy regimen reduced the risk of death by 35% (hazard ratio [HR] 0.65; 95% CI: 0.52–0.80), improving from an HR of 0.72 at the first interim analysis. 2946P Exposure-Adjusted Analyses of Safety Patterns in HERIZON-GEA-01: Zanidatamab With and Without Tislelizumab and Chemotherapy in 1L HER2-Positive Metastatic Gastroesophageal Adenocarcinoma • In the exposure-adjusted event rate analysis, after accounting for differences in treatment exposure, all grade and grade ≥3 diarrhea TEAE rates were generally comparable between the zanidatamab + tislelizumab + Chemotherapy and zanidatamab + CT arms • In the per-cycle analysis, diarrhea TEAE incidence generally decreased over successive treatment cycles, during which CT could be reduced or discontinued per protocol or standard of care –TEAEs leading to zanidatamab or trastuzumab discontinuation also generally decreased over successive cycles in each treatment arm
Page 22
Closing 22 Adam Schayowitz Head of R&D
Page 23
23 Executing on a model that combines R&D and acquisitions to compound value for shareholders 1 Immediate revenue Upfronts and development milestones 2 Strategic validation Early-stage partnering and shared risk 3 Compounding platform Commercial milestones and future royalties 1 Ongoing pipeline development 2 Partnerships & Spinouts 3 Continued innovation in R&D R&D provides upside optionality Early-stage partnering provides funding for future R&D and shared risk profile • ZW191 & ZW251 Phase 1 trials Pan-RAS ADC platform unveiled with three new candidates Evaluating opportunities both within wholly owned pipeline and acquired assets from Theravance Biopharma
Page 24
Q&A Q&A Ken Galbraith Chair & Chief Executive Officer Adam Schayowitz EVP & Head of R&D 24 Sabeen Mekan Chief Medical Officer Paul Moore Chief Scientific Officer